EFFICACY AND SAFETY OF BRIVEKIMIG (A DUAL-TARGET, ANTITUMOUR NECROSIS FACTOR AND ANTI-OX40 LIGAND NANOBODY®) IN PARTICIPANTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA: IMPLICATIONS FOR INFLAMMATORY BOWEL DISEASES

Authors
Category Primary study
ConferenceDigestive Disease Week 2026, DDW 2026
Year 2026
This article has no abstract
Epistemonikos ID: c81fc9cb65ebfd092094272fef697e920c74b040
First added on: Sep 12, 2026